Co-expression of CCR5, CXCR6, and CXCR3 provides a functional ‘code’ that separates T-cell-mediated anti-tumor efficacy from off-target toxicity, enabling the selection of superior cells for safer and more effective cancer immunotherapies. Here, CXCR6 is linked to neoplasm.